If you're feeling good about the market, you're not alone. Take my hand as we go over some of this week's more uplifting headlines.

1. Apple 2,000,000, Skeptics 0
Apple (Nasdaq: AAPL) didn't just get lucky in selling a million iPads to early adopters in its first month on the market. The class of Cupertino reported on Monday that it has now passed the 2 million mark, less than two months since the debut.

Apple was assisted by iPad's rollout in a few markets abroad this past weekend, but clearly the supersized iPod touch is resonating with consumers.

With 5,000 iPad-specific applications -- and an App Store brimming with more than 200,000 iPhone and iPod touch programs that mostly work with the iPad -- Apple has another hit on its hands.

2. Them bones
Amgen (Nasdaq: AMGN) may have another hit drug on its hands. The Food and Drug Administration has approved Prolia, Amgen's osteoporosis treatment for postmenopausal women.

Amgen is no stranger to blockbusters. It went from fledgling biotech to a major pharmaceuticals player with the success of its Neupogen and Epogen drugs. However, approved drugs do come with a ticking clock that counts down the days until they go off patent, opening up the gates to generic knockoffs. Amgen needed its pipeline to come through, and it appears to have done just that with Prolia.

3. Reel good news
The big screen continues to widen for IMAX (Nasdaq: IMAX). The provider of premium sight and sound cinematic experiences will team up with exhibitor AMC to grow its empire. The two companies have agreed to open another 15 to 25 screens next year. The original deal only covers the 104 theaters set to be up by the end of this year.

This is a pretty important deal for IMAX, because it also validates the concept. Earlier this year, AMC opened an enhanced screen in Florida. With the arrival of AMC ETX, it was easy to wonder if AMC was straying from the original joint-venture arrangement with IMAX.

AMC ETX may not necessarily be kicking the popcorn bucket, but the new deal extends the partnership for an additional three years. If AMC was set to go it alone, it wouldn't have beefed up its alliance with IMAX.

4. The dormant social network with 280 million unsuspecting snoozers
Yahoo! (Nasdaq: YHOO) is starting to advise its base of 280 million email users to check their privacy settings, ahead of launching a new set of social features later this month.

Yahoo! has seen the privacy missteps at Facebook and Google's (Nasdaq: GOOG) Buzz, so it's making sure that it shows its hand early and often. It will also make opting out as simple as a mouse click.

The odds are long for Yahoo! to make a dent in social networking, but it's certainly attacking the opportunity from a position of strength. Yahoo! watches over more email accounts than Microsoft's (Nasdaq: MSFT) Windows Live Hotmail and Google's Gmail -- its two nearest rivals -- combined.

However, Yahoo!'s email service is the only one of the three to decline in usage over the past year, according to Internet traffic tracker comScore. In other words, it may as well strike while the iron is hotter than it's likely to be in the future.

5. Boeing places
Boeing (NYSE: BA) is flying high in Russia. The aircraft giant beat out Airbus and United Aircraft to land an order for as many as 65 new planes for Russian Technologies, which operates carrier Rosavia.

Sure, having three desperate companies vying to sell aircraft is likely to translate into a better deal for the buyer than the seller. However, given the iffy state of many carriers, any fleet-expanding order is a welcome one.

Google and IMAX are Motley Fool Rule Breakers recommendations. Apple is a Stock Advisor selection. Motley Fool Options has recommended a diagonal call position on Microsoft, which is an Inside Value pick. Try any of our Foolish newsletter services, free for 30 days.

Longtime Fool contributor Rick Munarriz is an optimist at every turn. Hdoes not own shares in any of the stocks in this story. Rick is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early. The Fool has a disclosure policy.